

First-line rituximab combined with short-term prednisolone treatment of pemphigus (Ritux 3): a prospective, multicentre, randomised trial

Lancet, The

389, 2031-2040

DOI: [10.1016/s0140-6736\(17\)30070-3](https://doi.org/10.1016/s0140-6736(17)30070-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pemphigus. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17026.	18.1	371
2	Rituximab as first-line treatment of pemphigus. <i>Lancet, The</i> , 2017, 389, 1956-1958.	6.3	40
3	Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. <i>International Immunopharmacology</i> , 2017, 53, 133-142.	1.7	37
4	The BLISTER study: possible overestimation of tetracycline efficacy – Authors' reply. <i>Lancet, The</i> , 2017, 390, 735-736.	6.3	1
6	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
7	Rituximab and short-course prednisone as the new gold standard for new-onset pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2017, 177, 1143-1144.	1.4	14
8	British Association of Dermatologists'™ guidelines for the management of pemphigus vulgaris 2017. <i>British Journal of Dermatology</i> , 2017, 177, 1170-1201.	1.4	163
9	New insights into pemphigoid diseases. <i>Experimental Dermatology</i> , 2017, 26, 1151-1153.	1.4	1
11	Mechanisms of Autoantibody-Induced Pathology. <i>Frontiers in Immunology</i> , 2017, 8, 603.	2.2	377
12	Crosstalk between Signaling Pathways in Pemphigus: A Role for Endoplasmic Reticulum Stress in p38 Mitogen-Activated Protein Kinase Activation?. <i>Frontiers in Immunology</i> , 2017, 8, 1022.	2.2	16
13	Rituximab: Revolutionizing the Treatment of Pemphigus. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 177-178.	0.2	1
14	IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 92-103.	1.8	54
15	Dermatosis ampollares. <i>Medicine</i> , 2018, 12, 2838-2845.	0.0	0
16	COPD and lung cancer in patients with pemphigus- a population based study. <i>Respiratory Medicine</i> , 2018, 136, 93-97.	1.3	5
17	Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 154-165.	1.8	34
18	Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 806-808.	0.6	32
19	Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 1-25.	2.9	135
20	The molecular basis of immune regulation in autoimmunity. <i>Clinical Science</i> , 2018, 132, 43-67.	1.8	20

#	ARTICLE	IF	CITATIONS
21	Rituximab as Single Long-term Maintenance Therapy in Patients With Difficult-to-Treat Pemphigus. <i>JAMA Dermatology</i> , 2018, 154, 363.	2.0	22
22	Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. <i>Internal Medicine</i> , 2018, 57, 2395-2398.	0.3	14
23	A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 97-103.	0.6	30
25	Rituximab in pemphigus. <i>Immunotherapy</i> , 2018, 10, 27-37.	1.0	31
26	Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. <i>International Immunopharmacology</i> , 2018, 54, 131-138.	1.7	70
27	FR-Rituximab, una revoluci3n en el tratamiento del p4nfigo. <i>Actas Dermo-sifilogr4ficas</i> , 2018, 109, 177-178.	0.2	0
28	Recent advances in the understanding and treatment of pemphigus and pemphigoid. <i>F1000Research</i> , 2018, 7, 1360.	0.8	11
29	Autoimmune Blistering Disorders in the Geriatric Population. <i>Current Geriatrics Reports</i> , 2018, 7, 243-249.	1.1	0
30	Pemphigus Foliaceus4 Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report. <i>Frontiers in Medicine</i> , 2018, 5, 315.	1.2	2
31	Long-Term Increase of Kcnn4 Potassium Channel4Surface Expression on B Cells in Pemphigus4Patients4after Rituximab Treatment. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2666-2668.	0.3	11
32	The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. <i>Current Opinion in Immunology</i> , 2018, 55, 81-88.	2.4	37
33	Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. <i>PLoS ONE</i> , 2018, 13, e0198074.	1.1	15
34	Immunoabsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1935.	2.2	20
35	Targeted Therapies for Autoimmune Bullous Diseases: Current Status. <i>Drugs</i> , 2018, 78, 1527-1548.	4.9	74
36	The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. <i>Dermatologic Therapy</i> , 2018, 31, e12726.	0.8	21
37	Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. <i>Dermatologic Therapy</i> , 2018, 31, e12671.	0.8	12
38	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018, 5, 306.	1.2	27
39	Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. <i>Dermatologic Therapy</i> , 2018, 31, e12696.	0.8	17

#	ARTICLE	IF	CITATIONS
40	The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review. <i>Frontiers in Immunology</i> , 2018, 9, 2056.	2.2	67
41	Current Therapy in Autoimmune Bullous Diseases. , 2018, , .		1
42	Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris. <i>Cell Reports</i> , 2018, 24, 2370-2380.	2.9	23
43	Emerging treatment options for the management of pemphigus vulgaris. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 757-778.	0.9	57
44	A New Classification System for IgG4 Autoantibodies. <i>Frontiers in Immunology</i> , 2018, 9, 97.	2.2	93
45	Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 248.	2.2	76
46	B Cell Modulation Strategies in Autoimmune Diseases: New Concepts. <i>Frontiers in Immunology</i> , 2018, 9, 622.	2.2	96
47	Humoral Epitope Spreading in Autoimmune Bullous Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 779.	2.2	77
48	Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions. <i>Frontiers in Immunology</i> , 2018, 9, 810.	2.2	18
49	Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. <i>Frontiers in Immunology</i> , 2018, 9, 1189.	2.2	27
50	Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. <i>Autoimmunity Reviews</i> , 2018, 17, 1002-1010.	2.5	60
51	Rituximab/IVIg in pemphigus " a 10-year study with a long follow-up. <i>Journal of Dermatological Treatment</i> , 2019, 30, 170-175.	1.1	8
52	Validity of the <sc>EQ</sc> " in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, 802-809.	1.4	27
53	Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. <i>Journal of Dermatological Treatment</i> , 2019, 30, 346-349.	1.1	11
54	Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. <i>Journal of Dermatological Treatment</i> , 2019, 30, 340-345.	1.1	8
55	Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 740-746.	0.6	48
56	Methylprednisolone pulse therapy plus adjuvant therapy for pemphigus vulgaris: an analysis of 10" years' experience on 312 patients. <i>Dermatologic Therapy</i> , 2019, 32, e13057.	0.8	8
57	Clinical efficacy of rituximab in the treatment of pemphigus vulgaris: A 10" year follow-up. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 861-862.	1.4	3

#	ARTICLE	IF	CITATIONS
58	From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2239-2252.	1.3	10
59	Pemphigus: Current and Future Therapeutic Strategies. <i>Frontiers in Immunology</i> , 2019, 10, 1418.	2.2	153
60	Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease. <i>Cell Reports</i> , 2019, 28, 909-922.e6.	2.9	31
61	Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature. <i>Pediatric Dermatology</i> , 2019, 36, 646-650.	0.5	15
62	Pemphigus vulgaris. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 264-278.	0.5	75
64	Iranian guideline for rituximab therapy in pemphigus patients. <i>Dermatologic Therapy</i> , 2019, 32, e13016.	0.8	28
65	Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. <i>JAMA Dermatology</i> , 2019, 155, 1404.	2.0	42
66	Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab. <i>International Journal of Women's Dermatology</i> , 2019, 5, 372-377.	1.1	11
69	<p>Management of chronic wounds in patients with pemphigus</p>. <i>Chronic Wound Care Management and Research</i> , 0, Volume 6, 89-98.	0.4	6
70	Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen. <i>Frontiers in Immunology</i> , 2019, 10, 1794.	2.2	20
71	Pemphigus. <i>Lancet, The</i> , 2019, 394, 882-894.	6.3	312
72	Bullous Diseases in Children: A Review of Clinical Features and Treatment Options. <i>Paediatric Drugs</i> , 2019, 21, 345-356.	1.3	13
73	The pathogenesis of bullous skin diseases. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100014.	2.0	21
74	Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide. <i>Current Dermatology Reports</i> , 2019, 8, 208-218.	1.1	2
75	What is novel in the clinical management of pemphigus. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 973-980.	1.3	14
76	Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 1990.	2.2	133
77	On the mark: genetically engineered immunotherapies for autoimmunity. <i>Current Opinion in Immunology</i> , 2019, 61, 69-73.	2.4	9
78	Treatment of pemphigus vulgaris: part 2 " emerging therapies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1061-1071.	1.3	13

#	ARTICLE	IF	CITATIONS
79	Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran: A multiple cross-sectional study. <i>Dermatologic Therapy</i> , 2019, 32, e12827.	0.8	2
80	Epidermolysis Bullosa Acquisita: The 2019 Update. <i>Frontiers in Medicine</i> , 2018, 5, 362.	1.2	91
81	Pharmacotherapeutic Approaches in Oral Medicine. , 2019, , 401-470.		1
82	Oral Vesicular and Bullous Lesions. , 2019, , 1083-1142.		0
83	Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 20-32.	0.5	31
84	Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 33-47.	0.5	40
86	Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies. <i>British Journal of Dermatology</i> , 2019, 181, 1101-1103.	1.4	6
87	World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. <i>Oral Diseases</i> , 2019, 25, 111-121.	1.5	13
88	Skin Barrier and Autoimmunity: Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin. <i>Frontiers in Immunology</i> , 2019, 10, 1089.	2.2	19
89	Current Clinical Trials in Pemphigus and Pemphigoid. <i>Frontiers in Immunology</i> , 2019, 10, 978.	2.2	63
90	Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: A case report and brief literature review. <i>IDCases</i> , 2019, 17, e00558.	0.4	12
91	Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 179-186.	0.6	50
93	Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases. <i>International Immunopharmacology</i> , 2019, 71, 40-42.	1.7	17
95	Skin-Associated B Cells in Health and Inflammation. <i>Journal of Immunology</i> , 2019, 202, 1659-1666.	0.4	57
96	Drug Discovery for Pemphigoid Diseases. <i>Current Protocols in Pharmacology</i> , 2019, 84, e55.	4.0	24
97	Long-term evaluation of pemphigus vulgaris: A retrospective consideration of 98 patients treated in an oral medicine unit in north-west Italy. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 406-412.	1.4	15
98	B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. <i>Scientific Reports</i> , 2019, 9, 3525.	1.6	24
99	Translational Use of a Standardized Full Human Skin Organ Culture Model in Autoimmune Blistering Diseases. <i>Current Protocols in Pharmacology</i> , 2019, 85, e56.	4.0	11

#	ARTICLE	IF	CITATIONS
100	Editorial: Autoantibodies. <i>Frontiers in Immunology</i> , 2019, 10, 484.	2.2	3
102	Pharmacological advances in pemphigus. <i>Current Opinion in Pharmacology</i> , 2019, 46, 44-49.	1.7	13
103	Editorial: Skin Blistering Diseases. <i>Frontiers in Medicine</i> , 2019, 6, 60.	1.2	1
104	Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 349-358.	2.5	81
105	Treatment Update of Autoimmune Blistering Diseases. <i>Dermatologic Clinics</i> , 2019, 37, 215-228.	1.0	22
106	Refractory pemphigus foliaceus treated with rituximab. <i>BMJ Case Reports</i> , 2019, 12, e229026.	0.2	4
108	Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2019, 6, 259.	1.2	3
111	Biological therapy of autoimmune blistering diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 149-156.	1.4	7
112	Use of synthetic and biologic DMARDs during pregnancy. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 27-39.	1.3	7
114	Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?. <i>Archives of Dermatological Research</i> , 2019, 311, 63-69.	1.1	28
115	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 575-585.e1.	0.6	224
116	Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 230-237.	0.8	8
117	Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. <i>Clinics in Dermatology</i> , 2020, 38, 384-396.	0.8	14
118	Autoimmune Bullous Skin Diseases: Pemphigus and Pemphigoid. , 2020, , 1191-1210.		0
119	Ocular surface involvement in pemphigus vulgaris: An interdisciplinary review. <i>Ocular Surface</i> , 2020, 18, 40-46.	2.2	6
120	Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up. <i>International Journal of Dermatology</i> , 2020, 59, 76-81.	0.5	15
121	Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. <i>International Journal of Immunogenetics</i> , 2020, 47, 41-49.	0.8	10
122	Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. <i>British Journal of Dermatology</i> , 2020, 183, 121-127.	1.4	13

#	ARTICLE	IF	CITATIONS
123	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.4	55
124	Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. <i>Autoimmunity Reviews</i> , 2020, 19, 102466.	2.5	53
125	Novedades terapéuticas en dermatología. <i>Piel</i> , 2020, 35, 4-9.	0.0	0
126	Cerebral toxoplasmosis after rituximab for pemphigus vulgaris. <i>JAAD Case Reports</i> , 2020, 6, 37-41.	0.4	10
127	Rituximab: A Review in Pemphigus Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 149-156.	3.3	42
128	The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 177-180.	1.4	5
129	Tissue-specific personalized medicine: the next level of individualized treatment. <i>British Journal of Dermatology</i> , 2020, 182, 833-834.	1.4	0
130	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. <i>Blood Advances</i> , 2020, 4, 4292-4295.	2.5	9
131	Geriatric Vulvar Dermatology. <i>Current Geriatrics Reports</i> , 2020, 9, 183-191.	1.1	0
132	Therapy Changes During Pemphigus Management: A Retrospective Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 581820.	1.2	3
133	Rituximab-mediated late onset neutropenia in autoimmune blistering diseases: negligible or underestimated threat?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1162-1164.	0.4	1
134	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020, 7, 553075.	1.2	7
135	Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience. <i>Dermatology</i> , 2021, 237, 179-184.	0.9	4
136	Immunizations in immunocompromised patients: a guide for dermatologists. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 699-723.	0.4	11
137	The efficacy of rituximab in patients with mucous membrane pemphigoid. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1084-1090.	1.1	11
138	Refractory pemphigus vulgaris successfully treated with ofatumumab. <i>JAAD Case Reports</i> , 2020, 6, 734-736.	0.4	10
139	Adverse electrocardiographic effects of rituximab infusion in pemphigus patients. <i>Dermatologic Therapy</i> , 2020, 33, e14299.	0.8	3
140	Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. <i>Dermatologic Therapy</i> , 2020, 33, e14380.	0.8	3

#	ARTICLE	IF	CITATIONS
142	<i>Chromosome 2q33</i>genetic polymorphisms in Tunisian endemic pemphigus foliaceus. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1476.	0.6	2
143	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1900-1913.	1.3	159
144	Novel Therapies for Pemphigus Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 765-782.	3.3	9
145	Identification of novel therapeutic targets for blocking acantholysis in pemphigus. <i>British Journal of Pharmacology</i> , 2020, 177, 5114-5130.	2.7	20
146	Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseasesâ€”Implications for Therapeutic Approaches. <i>Cells</i> , 2020, 9, 2627.	1.8	24
147	Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study. <i>Dermatologic Therapy</i> , 2020, 33, e14407.	0.8	5
148	Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases. <i>European Journal of Immunology</i> , 2020, 50, 1885-1894.	1.6	9
149	Chinese Expert Proposal on the Diagnosis and Management of Pemphigus Vulgaris (2020)#. <i>International Journal of Dermatology and Venereology</i> , 2020, 3, 148-155.	0.1	3
150	Long-term outcomes of rituximab therapy in pemphigus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2884-2889.	1.3	15
151	Rationale for including intravenous immunoglobulin in the multidrug protocol of curative treatment of pemphigus vulgaris and development of an assay predicting disease relapse. <i>International Immunopharmacology</i> , 2020, 82, 106385.	1.7	4
152	Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 523-524.	0.6	1
153	Pemphigoid nodularis: An infrequent variant responding to rituximab. <i>Australasian Journal of Dermatology</i> , 2020, 61, e438-e439.	0.4	1
154	S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 516-526.	0.4	20
155	PÃ©nfigo vulgar: estudio de cohorte retrospectivo de sus caracterÃ©sticas clÃ©nicas, tratamientos empleados y evoluciÃ³n. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2020, 111, 398-407.	0.2	8
156	Emerging treatments for bullous pemphigoid. <i>Journal of Dermatological Treatment</i> , 2022, 33, 649-661.	1.1	10
158	Low prevalence of late-onset neutropenia after rituximab treatment in patients with pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1824-1825.	0.6	3
159	The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: Daily practice data from a retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1503-1505.	0.6	9
160	Complete remission on minimal therapy vs. off therapy: for what should we be aiming in pemphigus?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e404-e405.	1.3	1

#	ARTICLE	IF	CITATIONS
161	A milestone in reaching the goal of complete remission offâ€therapy in pemphigus. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e405.	1.3	0
162	Recent Advances in Understanding Pemphigus and Bullous Pemphigoid. Journal of Investigative Dermatology, 2020, 140, 733-741.	0.3	37
163	Osteoporosis and bone health in autoimmune blistering skin diseaseâ€an evidenced based review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2745-2756.	1.3	1
164	Pemphigus Vulgaris: A Retrospective Cohort Study of Clinical Features, Treatments, and Outcomes. Actas Dermo-sifiliogrÃficas, 2020, 111, 398-407.	0.2	0
165	COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience. Journal of Dermatological Treatment, 2022, 33, 1181-1182.	1.1	15
166	Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin. Journal of Allergy and Clinical Immunology, 2020, 146, 8-16.	1.5	44
167	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. Journal of the American Academy of Dermatology, 2020, 83, 1150-1159.	0.6	27
168	Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. Journal of Dermatological Treatment, 2022, 33, 869-874.	1.1	13
169	Infection risk of dermatologic therapeutics during the COVIDâ€19 pandemic: an evidenceâ€based recalibration. International Journal of Dermatology, 2020, 59, 1043-1056.	0.5	19
170	Ultra-low dose rituximab for refractory pemphigus vulgaris: a pilot study. Expert Opinion on Biological Therapy, 2020, 20, 673-678.	1.4	18
171	CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors. Frontiers in Immunology, 2020, 11, 32.	2.2	84
172	Pathogenic and protective roles of cytokines in pemphigus: A systematic review. Cytokine, 2020, 129, 155026.	1.4	23
173	Is Local Production of Autoantibodies in Skin Lesions Relevant in Pemphigus?. Journal of Investigative Dermatology, 2020, 140, 275-276.	0.3	2
174	Rituximab with prednisolone as firstâ€line treatment in pemphigus vulgaris. British Journal of Dermatology, 2020, 182, 1078-1079.	1.4	1
175	Experiencia con rituximab en el tratamiento de las enfermedades ampollares autoinmunes. Piel, 2020, 35, 16-21.	0.0	0
176	Treatment with antiâ€neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. British Journal of Pharmacology, 2020, 177, 2381-2392.	2.7	20
177	Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. Immunopharmacology and Immunotoxicology, 2020, 42, 56-58.	1.1	22
178	Anti-CD20â€mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney International, 2020, 97, 885-893.	2.6	32

#	ARTICLE	IF	CITATIONS
179	Results of the guideline-based treatment for pemphigus: a single-centre experience with 84 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1324-1330.	1.3	14
180	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	2.0	40
181	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, e235-e236.	0.6	53
182	Autoimmune bullous skin diseases, pemphigus and pemphigoid. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1031-1047.	1.5	105
183	Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e302-e303.	1.3	53
184	Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 443-446.	0.3	1
185	Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 33-40.	1.1	20
186	Reader Comment on "Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris". <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 111-112.	0.6	0
187	Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 176-186.	0.6	8
189	Clinical and biological activity of rituximab in the treatment of pemphigus. <i>Immunotherapy</i> , 2021, 13, 35-53.	1.0	2
190	Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e14405.	0.8	11
191	A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 92-97.	1.4	4
192	Sulfasalazine treatment for persistent pemphigus vulgaris oral lesions after rituximab treatment. <i>Australasian Journal of Dermatology</i> , 2021, 62, e303-e306.	0.4	0
193	Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. <i>Dermatologic Therapy</i> , 2021, 34, e14633.	0.8	11
194	Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 96-122.	0.2	26
195	COVID-19: The experience from Iran. <i>Clinics in Dermatology</i> , 2021, 39, 23-32.	0.8	11
196	Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?. <i>Dermatologic Therapy</i> , 2021, 34, e14647.	0.8	11
197	Reply to "Treatment considerations for patients with pemphigus during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e59-e60.	0.6	4

#	ARTICLE	IF	CITATIONS
198	Doubleâ€filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10â€years' experience of a single center in China. <i>Journal of Clinical Apheresis</i> , 2021, 36, 20-27.	0.7	6
200	Septic shock in a refractory pemphigus vulgaris patient after rituximab therapy. <i>Dermatologic Therapy</i> , 2021, 34, e14725.	0.8	3
201	A 10-year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1643-1645.	0.6	4
202	Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00535.	0.6	1
203	Treatment of Pemphigus with Rituximab: Real-Life Experience in a Cohort of 117 Patients in Israel. <i>Dermatology</i> , 2021, 237, 450-456.	0.9	3
204	A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?. <i>Frontiers in Immunology</i> , 2020, 11, 613435.	2.2	22
205	Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3.	1.1	3
206	Hematological Inflammatory Markers in Patients with Pemphigus Vulgaris. <i>Dermatology</i> , 2021, 237, 912-920.	0.9	7
207	Autoimmune Bullous Diseases. , 2021, , 1-34.		0
208	Milestones in Personalized Medicine in Pemphigus and Pemphigoid. <i>Frontiers in Immunology</i> , 2020, 11, 591971.	2.2	17
209	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 797-806.	1.3	6
210	Comparison of three different dose regimens of methylprednisolone as initial therapy for pemphigus vulgaris of moderate severity: A singleâ€center retrospective study from Turkey. <i>Australasian Journal of Dermatology</i> , 2021, 62, 199-205.	0.4	1
211	Analysis of clinical and diagnostic features and criteria for the effectiveness of treatment of autoimmune bullous dermatoses pemphigus group. <i>Ukrainian Journal of Dermatology Venerology Cosmetology</i> , 2021, , 51-57.	0.0	0
212	The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 443-454.	1.4	5
213	Epidemiology of Pemphigus. <i>JID Innovations</i> , 2021, 1, 100004.	1.2	51
214	Editorial: Skin Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 627565.	2.2	1
215	Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab. <i>Frontiers in Immunology</i> , 2021, 12, 665522.	2.2	10
216	Rituximab in pemphigus vulgaris - Standard operating procedure. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0

#	ARTICLE	IF	CITATIONS
217	Rituximab Therapy for Treatment of Pemphigus in Southeast Asians. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1677-1690.	2.0	7
218	Pemphigus Vulgaris and Bullous Pemphigoid of the Upper Aerodigestive Tract: A Review Article and Novel Approaches to Management. <i>Orl</i> , 2021, 83, 395-403.	0.6	5
219	Impact of COVID-19 on autoimmune blistering diseases. <i>Clinics in Dermatology</i> , 2021, 39, 359-368.	0.8	14
220	B-cell targeted therapies in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	1
221	Paraneoplastic autoimmune multiorgan syndrome. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	6
222	Pemphigus: a critical analysis on clinical subtypes, pathogenesis, diagnostics and established novel therapeutics. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	1
223	Immunobullous disease. <i>Clinical Medicine</i> , 2021, 21, 162-165.	0.8	4
224	Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus. <i>Journal of Dermatological Treatment</i> , 2021, , 1-31.	1.1	1
225	B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells. <i>Cells</i> , 2021, 10, 1190.	1.8	22
226	Clinicians' pearls and myths in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 142-146.	0.1	0
227	Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen. <i>Frontiers in Immunology</i> , 2021, 12, 666022.	2.2	4
228	Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2858-2865.e4.	0.3	24
230	Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. <i>New England Journal of Medicine</i> , 2021, 384, 2295-2305.	13.9	58
231	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1523-1537.	0.6	11
232	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. <i>British Journal of Dermatology</i> , 2021, 185, 745-755.	1.4	42
233	Bullous autoimmune dermatoses: clinical features, diagnostic evaluation, and treatment options. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, 413-420.	0.6	21
235	Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders. <i>Frontiers in Immunology</i> , 2021, 12, 686466.	2.2	19
236	Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study. <i>International Immunopharmacology</i> , 2021, 96, 107755.	1.7	28

#	ARTICLE	IF	CITATIONS
237	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1926-1948.	1.3	86
238	Treatment and monitoring of an immunobullous disease cohort in a single centre in Sydney Australia. <i>Australasian Journal of Dermatology</i> , 2021, 62, e437-e440.	0.4	1
239	Therapeutic approaches and targets for treatment of autoimmune bullous diseases. <i>Dermatologic Therapy</i> , 2021, 34, e15032.	0.8	1
240	A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 507-518.	1.1	17
241	Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, , 120347542110350.	0.6	0
242	Biologics in autoimmune bullous diseases: Current scenario. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 611-620.	0.2	3
243	Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 351-362.	2.9	15
244	State-of-the-art review of human autoimmune blistering diseases (AIBD). <i>Veterinary Dermatology</i> , 2021, 32, 524-e145.	0.4	0
245	Dermatose à IgA linéaire compliquée d'une aspergillose invasive. <i>La Presse Médicale Formation</i> , 2021, 2, 303-306.	0.1	0
246	Predicting the number of article citations on the topic of pemphigus vulgaris with the 100 top-cited articles since 2011. <i>Medicine (United States)</i> , 2021, 100, e26806.	0.4	25
247	Skin-Homing Regulatory B Cells Required for Suppression of Cutaneous Inflammation. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1995-2005.e6.	0.3	10
248	On the road to eliminating long-lived plasma cells—are we there yet?. <i>Immunological Reviews</i> , 2021, 303, 154-167.	2.8	13
249	Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 102931.	2.5	7
252	Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2132-2140.e1.	0.3	13
253	Malignancy Risks of Dermatologic Therapies. , 2021, , 149-190.		0
254	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. <i>Journal of Clinical Investigation</i> , 2020, 130, 6317-6324.	3.9	66
255	Drug Development in Pemphigoid Diseases. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00055-114.	0.6	10
256	Paraneoplastic autoimmune multiorgan syndrome. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 174-183.	0.1	8

#	ARTICLE	IF	CITATIONS
257	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. <i>Journal of Korean Medical Science</i> , 2020, 35, e335.	1.1	4
258	Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2020, 86, 39.	0.2	15
259	Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. <i>Dermatology Practical and Conceptual</i> , 2020, 10, e2020050.	0.5	40
260	Dapsone in the Management of Pemphigus and Pemphigoid: Rediscovery of its Long-Lost Efficacy. <i>Cureus</i> , 2020, 12, e8805.	0.2	1
261	Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1058-1064.e7.	0.3	9
262	Meilensteine der personalisierten Medizin bei Pemphigus und Pemphigoid. <i>Karger Kompass Autoimmun</i> , 0, , 1-8.	0.0	0
263	Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	4
264	Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial*. <i>British Journal of Dermatology</i> , 2022, 186, 429-439.	1.4	43
265	Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre. <i>International Journal of Clinical Practice</i> , 2021, 75, e14955.	0.8	1
266	An Updated Review of Pemphigus Diseases. <i>Medicina (Lithuania)</i> , 2021, 57, 1080.	0.8	25
267	Ultralow-dose rituximab in pemphigus: a single-centre experience. <i>British Journal of Dermatology</i> , 2022, 186, 581-583.	1.4	2
268	Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment. <i>Biomedicines</i> , 2021, 9, 1411.	1.4	1
269	Oral Vesicular and Bullous Lesions. , 2018, , 1-60.		0
270	Pharmacotherapeutic Approaches in Oral Medicine. , 2018, , 1-70.		0
272	PÃ©nfigo: tratamiento y evoluci3n en nuestros pacientes. <i>Piel</i> , 2019, 34, 344-346.	0.0	0
273	Pemphigus vulgaris - approach and management (Review). <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 5056-5060.	0.8	16
274	Toxicity of glucocorticosteroids in autoimmune blistering diseases. <i>Mucosa</i> , 2019, 2, 59-67.	0.3	2
275	Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00286.	0.6	4

#	ARTICLE	IF	CITATIONS
276	Updates on diagnosis and management of autoimmune blistering diseases. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 46-64.	0.8	0
277	Pemphigus – The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic. <i>Biomedicines</i> , 2021, 9, 1555.	1.4	6
278	Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. <i>Journal of Investigative Dermatology</i> , 2022, 142, 907-914.	0.3	21
279	Immunotherapy for Autoimmune Diseases. , 2021, , 63-115.		0
280	Immune-mediated Disorders. , 2020, , 1-21.		17
281	Neue Arzneimittel 2019. , 2020, , 43-150.		2
282	Approaching a New Era of Pemphigus Treatment. <i>Nishinohon Journal of Dermatology</i> , 2020, 82, 5-9.	0.0	0
284	The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behcet's Disease: A Systematic Review. <i>Journal of Anesthesiology and Pain Therapy</i> , 2020, 1, 14-23.	0.0	0
285	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant. <i>Biomolecules</i> , 2021, 11, 1634.	1.8	0
286	Rituximab in Pemphigus: Road Covered and Challenges Ahead. <i>Indian Dermatology Online Journal</i> , 2018, 9, 367-372.	0.2	1
287	Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 197-206.	0.2	2
288	Management of Pemphigus in COVID-19 Pandemic Era; a Review Article. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e51.	0.2	10
289	Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. <i>Current Problems in Cancer</i> , 2022, 46, 100813.	1.0	3
291	Update on Myositis Therapy: from Today's Standards to Tomorrow's Possibilities. <i>Current Pharmaceutical Design</i> , 2021, 27, .	0.9	2
293	Therapeutic modalities and course of the disease in patients with autoimmune pemphigus (AP) treated at the Clinic of dermatovenerology in the period 2013-2018. <i>Medicinski Podmladak</i> , 2021, 72, 14-19.	0.2	0
296	Patient Quality of Life Improvement in Bullous Disease: A Review of Primary Literature and Considerations for the Clinician. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2022, Volume 15, 27-42.	0.8	2
297	Pemphigus Vulgaris: Present and Future Therapeutic Strategies. <i>Dermatology Practical and Conceptual</i> , 2022, 12, e2022037.	0.5	9
298	Autoimmune Pemphigus: Latest Advances and Emerging Therapies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 808536.	1.6	17

#	ARTICLE	IF	CITATIONS
299	Pathophysiology, Treatment and Diagnosis of IgG4-related Disease. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 295-300.	0.0	0
300	Immunopathology and Immunotherapy of Inflammatory Skin Diseases. Immune Network, 2022, 22, e7.	1.6	13
301	The demographic attributes, clinical features, and optimal management of 143 patients with pemphigus: A retrospective observational study from a tertiary care center of India. Indian Dermatology Online Journal, 2022, 13, 207.	0.2	2
303	Caspase Inhibition as a Possible Therapeutic Strategy for Pemphigus Vulgaris: A Systematic Review of Current Evidence. Biology, 2022, 11, 314.	1.3	0
304	Treatment of pemphigus in Australia: Aligning current practises with global recommendations. Australasian Journal of Dermatology, 2022, , .	0.4	0
305	Marked to Die-Cell Death Mechanisms for Keratinocyte Acantholysis in Pemphigus Diseases. Life, 2022, 12, 329.	1.1	1
306	Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients. Dermatologic Therapy, 2022, , e15397.	0.8	2
307	IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies. Frontiers in Immunology, 2022, 13, 834342.	2.2	14
308	Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis. Archives of Dermatological Research, 2023, 315, 207-213.	1.1	4
309	CD20-Antikörper Rituximab: Infektrisiko beherrschbar bei Pemphigustherapie. , 0, , .		0
310	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. Journal of Investigative Dermatology, 2022, 142, 811-822.	0.3	5
311	The Diversity of Serum Anti-DSC3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab. Frontiers in Immunology, 2022, 13, 849790.	2.2	1
312	Immunobiologicals in dermatology. Anais Brasileiros De Dermatologia, 2022, , .	0.5	1
313	Retrospective study of gingival involvement in pemphigus: A difficult to treat phenomenon. Dermatologic Therapy, 2022, 35, e15475.	0.8	3
314	Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris. Acta Dermato-Venereologica, 2022, 102, adv00679.	0.6	1
315	Advancement in therapeutic strategies for immune-mediated oral diseases. Disease-a-Month, 2023, 69, 101352.	0.4	6
316	Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clinical and Experimental Dermatology, 2022, 47, 1508-1516.	0.6	3
317	Relationship Between Pemphigus Vulgaris Severity and PCR-positive Herpes Simplex Virus. Acta Dermato-Venereologica, 2022, , .	0.6	4

#	ARTICLE	IF	CITATIONS
318	A case of pemphigus herpetiformis successfully treated with rituximab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
319	Autoimmune blistering diseases - diagnosis, therapy and introducing of biologics into therapeutical approach - part I. Dermatologie Pro Praxi, 2021, 15, 131-135.	0.1	0
320	Autoimmune blistering diseases - diagnosis, therapy and introducing of biologics into therapeutical approach - part II. Dermatologie Pro Praxi, 2021, 15, 195-202.	0.1	0
321	A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations. Cureus, 2021, 13, e20433.	0.2	0
322	A review of reported infectious events following rituximab therapy in pemphigus patients. Dermatologic Therapy, 2022, 35, e15264.	0.8	1
323	The pathogeneses of pemphigus and pemphigoid diseases. Journal of Dermatological Science, 2021, 104, 154-163.	1.0	13
334	Disease progression and response to therapy in pemphigus based on a registry. JDDG - Journal of the German Society of Dermatology, 2022, 20, 461-467.	0.4	5
335	Registerstudie zu Krankheitsentwicklung und Therapieansprechen bei Pemphigus. JDDG - Journal of the German Society of Dermatology, 2022, 20, 461-468.	0.4	0
336	Residents'corner, January-February 2018 What's new this month?. European Journal of Dermatology, 2018, 28, 134-135.	0.3	0
337	Rituximab in pemphigus: Road covered and challenges ahead. Indian Dermatology Online Journal, 2018, 9, 367.	0.2	7
338	Autoimmune Bullous Diseases. , 2022, , 829-862.		41
339	Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study. Frontiers in Immunology, 2022, 13, 884931.	2.2	3
340	FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Frontiers in Immunology, 2022, 13, .	2.2	9
341	Prominent B-Cell Signature Differentiates Discoid from Subacute Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2022, 142, 2885-2895.e2.	0.3	8
343	Pediatric Autoimmune Bullous Disease: A Literature Review and Update on Management. Pediatrics in Review, 2022, 43, 309-321.	0.2	1
344	Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. International Journal of Women's Dermatology, 2022, 8, e004.	1.1	2
346	Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview. Journal of Clinical Medicine, 2022, 11, 3528.	1.0	5
347	Immunotherapy for Pemphigus: Present and Future. Frontiers in Medicine, 0, 9, .	1.2	3

#	ARTICLE	IF	CITATIONS
348	Evaluation of Clinical Relevance and Biological Effects of Antiriximab Antibodies in Patients With Pemphigus. <i>JAMA Dermatology</i> , 2022, 158, 893.	2.0	1
349	Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 500-502.	0.6	1
350	Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
351	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	51
352	Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 4102.	1.0	2
353	Long-term efficacy and safety analysis of single cycle of biosimilar rituximab in pemphigus: A retrospective study of 76 patients from India. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	2
354	Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
356	Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris. <i>JAMA Dermatology</i> , 0, , .	2.0	0
357	Clinical severity scores as a guide for prediction of initial treatment responses in pemphigus and pemphigoid patients. <i>Journal of Dermatology</i> , 0, , .	0.6	0
358	IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab. <i>Biomedicines</i> , 2022, 10, 1774.	1.4	3
359	Nail Loss in Mild to Moderate Pemphigus Vulgaris. <i>Skin Appendage Disorders</i> , 2022, 8, 504-507.	0.5	2
360	Elevated serum level of B-cell activating factor (<sc>BAFF</sc>) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with <sc>anti-BAFF</sc> agents. <i>International Journal of Dermatology</i> , 2023, 62, 567-574.	0.5	2
361	Bullous systemic lupus erythematosus in females. <i>International Journal of Women's Dermatology</i> , 2022, 8, e034.	1.1	5
363	Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
364	CXCL12/CXCR4 Axis Drives the Chemotaxis and Differentiation of B Cells in Bullous Pemphigoid. <i>Journal of Investigative Dermatology</i> , 2023, 143, 197-208.e6.	0.3	3
365	Pemphigus for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 0, , .	1.1	0
366	Burden of pemphigus vulgaris with a particular focus on women: A review. <i>International Journal of Women's Dermatology</i> , 2022, 8, e056.	1.1	5
367	Off-Label Uses of Rituximab in Dermatology. <i>Current Dermatology Reports</i> , 0, , .	1.1	2

#	ARTICLE	IF	CITATIONS
368	Rituximab therapy for intractable pemphigus: A multicenter, open-label, single-arm, prospective study of 20 Japanese patients. <i>Journal of Dermatology</i> , 2023, 50, 175-182.	0.6	2
369	Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
370	Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. <i>Immune Network</i> , 2022, 22, .	1.6	3
371	Development and function of tissue-resident memory B cells. <i>Advances in Immunology</i> , 2022, , .	1.1	5
372	Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	5
373	Rituximab in the Management of a Child with Pemphigus Vulgaris: Case Study. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 0, , 407-413.	0.1	1
374	Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability. <i>Patient Preference and Adherence</i> , 0, Volume 16, 3035-3043.	0.8	1
375	Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris. <i>JAAD Case Reports</i> , 2023, 31, 16-18.	0.4	5
376	Electron microscopy of desmosomal structures in the pemphigus human skin organ culture model. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
377	PÃ©nfigo foliÃ©iceo tratado con Rituximab. <i>DermatologÃ©a Argentina</i> , 2022, 28, 40-42.	0.0	0
378	Autoimmune pre-disease. <i>Autoimmunity Reviews</i> , 2023, 22, 103236.	2.5	25
379	Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus. <i>JAMA Dermatology</i> , 2023, 159, 56.	2.0	5
380	Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab. <i>Clinical Pediatrics</i> , 0, , 000992282211408.	0.4	1
381	Clinical course and outcomes of pemphigus vulgaris and foliaceus: A retrospective study using a nationwide database in Japan. <i>Journal of Dermatology</i> , 2023, 50, 212-221.	0.6	1
382	BÃ©cell targeted therapy of pemphigus. <i>Journal of Dermatology</i> , 2023, 50, 124-131.	0.6	2
383	Taiwanese dermatological association (TDA) consensus for the management of pemphigus. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	1
384	T cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen. <i>Journal of Dermatology</i> , 2023, 50, 112-123.	0.6	5
385	Rituximab and risk of infections in patients with pemphigus: Answers from a global population-based cohort study. <i>British Journal of Dermatology</i> , 0, , .	1.4	1

#	ARTICLE	IF	CITATIONS
386	Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. American Journal of Clinical Dermatology, 0, , .	3.3	4
387	Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. British Journal of Dermatology, 2023, 188, 499-505.	1.4	6
388	B-cell depletion in the treatment of pemphigus: two clinical cases and literature review. AlĖ1manah KliniĖeskoj Mediciny, 0, , .	0.2	0
389	Treatment of pemphigus beyond rituximab: chimeric autoantibody receptor T cell (CAAR-T cell) therapy. Mucosa, 0, , 1-9.	0.3	0
390	Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues. Frontiers in Immunology, 0, 14, .	2.2	0
391	Editorial: Mechanism and therapy of autoimmune skin diseases. Frontiers in Medicine, 0, 10, .	1.2	0
392	Epidermolysis Bullosa AcquisitaĖ”Current and Emerging Treatments. Journal of Clinical Medicine, 2023, 12, 1139.	1.0	1
393	B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. Frontiers in Immunology, 0, 14, .	2.2	9
394	Editorial: Autoimmune pre-disease. Frontiers in Immunology, 0, 14, .	2.2	2
395	Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris. American Journal of Therapeutics, 2023, 30, e544-e546.	0.5	1
396	Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia. Frontiers in Medicine, 0, 10, .	1.2	2
397	Rituximab Therapy for Persistent, Severe and Extensive Idiopathic Bullous Pemphigoid. Journal of Cosmetics Dermatological Sciences and Applications, 2023, 13, 76-83.	0.1	0
398	Understanding CD4+ T cells in autoimmune bullous diseases. Frontiers in Immunology, 0, 14, .	2.2	1
410	Adverse events following rituximab therapy in pemphigus patients. , 2024, , 335-345.		0
412	Pemphigus Foliaceus and Pemphigus Erythematosus. , 2023, , 731-737.		0
413	Pemphigus Vulgaris. , 2023, , 745-758.		0
416	Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches. Clinical Reviews in Allergy and Immunology, 2023, 65, 331-353.	2.9	0
427	Tofacitinib for the treatment of severe rare skin diseases: a narrative review. European Journal of Clinical Pharmacology, 2024, 80, 481-492.	0.8	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------